Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13659653 | 0.93 | KMT2A (0.50) | KMT2AMEN1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL404661 | 0.92 | KMT2A (0.49) | KMT2AMEN1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL405405 | 0.89 | KMT2A (0.48) | KMT2AMEN1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL13655005 | 0.88 | KDM4E (0.43) | KMT2AMEN1KDM4E | |
| SCHEMBL13655008 | 0.88 | KDM4E (0.41) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL1109325 | 0.84 | KMT2A (0.52) | KMT2AMEN1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL13655015 | 0.84 | MAPT (0.47) | KDM4EANPEP | |
| SCHEMBL13655035 | 0.83 | HDAC1 (0.41) | — | |
| SCHEMBL404237 | 0.83 | DGAT1 (0.39) | KMT2AMEN1 | |
| SCHEMBL13655030 | 0.83 | LMNA (0.43) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247506-A1 | Antibacterial agents | CHIRON CORPORATION | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247506-A1 | Antibacterial agents | MRPL21, SI, PGLS | KMT2A 4800/4885MEN1 2414/4885KDM4E 4327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.